from the Innova's website PDF Test Reporting A
Post# of 22456
(Total Views: 265)
Posted On: 02/12/2021 2:48:31 AM
Re: Puravida19 #17555
from the Innova's website PDF
Test Reporting
A rapid test identifies a foreign antigen, in this gcase the nucleocapsid antigen from SARS-CoV-2.
An antigen means anything that stimulates a response in the immune system. These inexpensive tests are simple to manufacture and scale up. But, most importantly, rapid antigen tests can identify the “infectious” early, even a day after coronavirus transmission.
Test results are read visually. Strong positive results can be reported at 20 minutes; while negative results can be read in 30 minutes.
As the test does not require equipment or need to be processed in a CLIA lab, the Innova rapid antigen test can be used at point-of-care settings, in areas marked as high-transmission.
Under Operation Moonshot, the United Kingdom chose Innova’s test kits over hundreds of competitors to screen both asymptomatic and symptomatic subjects in community settings.
In July 2020, after completing clinical trials
in several countries, Innova announced
the market availability of one the world’s
first Rapid SARS-CoV-2 Antigen Test Kits.
Innova has shipped over 200M+ antigen
test kits, to date.
After the app is downloaded from the App
Store® or Google Play®, test results can be captured and personalized with the QDX open architecture. The encrypted blockchain hetechnology ensures security as data is shared with any cloud-based platform. No personal health information is stored, in compliance with HIPAA and HL7 regulations.
App users can administer health questionnaires, collect on-site temperatures, and record authenticated results for both antibody and antigen tests. The app displays a green, yellow, or red “badge” to indicate the user’s health
status.
Through our proprietary COVIDlyticsTM systems, test results can be transferred to city, state, and federal public health agencies.
After quickly verifying infection, this “health passport” will help prevent further virus spread and allow return to normal life
Test Reporting
A rapid test identifies a foreign antigen, in this gcase the nucleocapsid antigen from SARS-CoV-2.
An antigen means anything that stimulates a response in the immune system. These inexpensive tests are simple to manufacture and scale up. But, most importantly, rapid antigen tests can identify the “infectious” early, even a day after coronavirus transmission.
Test results are read visually. Strong positive results can be reported at 20 minutes; while negative results can be read in 30 minutes.
As the test does not require equipment or need to be processed in a CLIA lab, the Innova rapid antigen test can be used at point-of-care settings, in areas marked as high-transmission.
Under Operation Moonshot, the United Kingdom chose Innova’s test kits over hundreds of competitors to screen both asymptomatic and symptomatic subjects in community settings.
In July 2020, after completing clinical trials
in several countries, Innova announced
the market availability of one the world’s
first Rapid SARS-CoV-2 Antigen Test Kits.
Innova has shipped over 200M+ antigen
test kits, to date.
After the app is downloaded from the App
Store® or Google Play®, test results can be captured and personalized with the QDX open architecture. The encrypted blockchain hetechnology ensures security as data is shared with any cloud-based platform. No personal health information is stored, in compliance with HIPAA and HL7 regulations.
App users can administer health questionnaires, collect on-site temperatures, and record authenticated results for both antibody and antigen tests. The app displays a green, yellow, or red “badge” to indicate the user’s health
status.
Through our proprietary COVIDlyticsTM systems, test results can be transferred to city, state, and federal public health agencies.
After quickly verifying infection, this “health passport” will help prevent further virus spread and allow return to normal life
(0)
(0)Quantum Materials Corp. (QTMM) Stock Research Links
Scroll down for more posts ▼